{"entity":{"id":"nct07391813","kind":"trial","name":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of SNB-101 in small-cell lung cancer, run by SN BioScience, now recruiting.","summary":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07391813 by SN BioScience, with 55 participants planned, started 2026-03 and due to reach its primary completion in 2028-12. Interventions recorded: SNB-101.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07391813","url":"https://clinicaltrials.gov/study/NCT07391813"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07391813","phase":"1/2","setting":"A Phase 1b/2, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of SNB-101, in Extensive Stage Small Cell Lung Cancer.","sponsor":"SN BioScience","enrolled":55,"outcomes":[]},"route":"/trials/nct07391813/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}]}}